A recent report from MarketsAndMarkets projected that the global gastric cancer market accounted for USD 3.01 billion in 2023 and is expected to reach USD 18.43 billion by 2034 with a CAGR of 17.92% ...

SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps”. Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug ...

As 2024 draws to a close, we explore five stocks to buy for a new year that promises opportunity alongside uncertainty ...

Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...